JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Список акций・Sanofi

Sanofi

Закрыт

43.37 0.18

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

43.08

Макс.

43.52

Ключевые показатели
By Trading Economics
Доход	2.4B 1.6B
Продажи	-961M 11B
P/E Средняя по отрасли	19.885 67.147
Прибыль на акцию	1.102
Рентабельность продаж	14.354
Сотрудники	74,846
EBITDA	-1.1B 2.7B

Рекомендации
By TipRanks
Рекомендации	Нейтрально
Прогноз на 12 месяцев	+22.26% upside

Рыночная статистика
By TradingEconomics
Рыночная капитализация	-11B 104B
Предыдущая цена открытия	43.19
Предыдущая цена закрытия	43.37

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

51.665 / 52.38 Поддержка и Сопротивление

Sanofi График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 апр. 2026 г., 06:12 UTC

Отчет

Sanofi Posts Higher Sales Amid Leadership Transition

12 февр. 2026 г., 12:40 UTC

Главные движущие силы рынка

Sanofi Shares Fall After CEO Change

29 янв. 2026 г., 11:35 UTC

Отчет

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

29 апр. 2026 г., 12:01 UTC

Отчет

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

27 апр. 2026 г., 09:32 UTC

Обсуждения рынка

Отчет

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 апр. 2026 г., 09:19 UTC

Обсуждения рынка

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 апр. 2026 г., 05:34 UTC

Отчет

Sanofi: 2026 Expectations Are at Constant Exchange Rates

23 апр. 2026 г., 05:34 UTC

Отчет

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

23 апр. 2026 г., 05:34 UTC

Отчет

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

23 апр. 2026 г., 05:34 UTC

Отчет

Sanofi Backs 2026 View

23 апр. 2026 г., 05:33 UTC

Отчет

Sanofi 1Q Business Net Pft EUR2.26B

23 апр. 2026 г., 05:33 UTC

Отчет

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

23 апр. 2026 г., 05:33 UTC

Отчет

Sanofi 1Q Business Oper Pft EUR2.97B

23 апр. 2026 г., 05:32 UTC

Отчет

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

23 апр. 2026 г., 05:32 UTC

Отчет

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

23 апр. 2026 г., 05:31 UTC

Отчет

Sanofi 1Q Net Sales EUR10.51B

10 апр. 2026 г., 11:12 UTC

Обсуждения рынка

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

10 апр. 2026 г., 10:54 UTC

Обсуждения рынка

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

30 мар. 2026 г., 10:40 UTC

Обсуждения рынка

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

27 мар. 2026 г., 10:40 UTC

Обсуждения рынка

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

11 мар. 2026 г., 11:02 UTC

Обсуждения рынка

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

24 февр. 2026 г., 14:00 UTC

Приобретения, слияния, поглощения

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

13 февр. 2026 г., 08:21 UTC

Обсуждения рынка

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

12 февр. 2026 г., 15:20 UTC

Отчет

Sanofi Shares Fall After CEO Change -- Update

10 февр. 2026 г., 14:07 UTC

Приобретения, слияния, поглощения

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

10 февр. 2026 г., 14:06 UTC

Приобретения, слияния, поглощения

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

10 февр. 2026 г., 14:05 UTC

Приобретения, слияния, поглощения

Sanofi Completes Acquisition of Dynavax

10 февр. 2026 г., 14:00 UTC

Приобретения, слияния, поглощения

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

6 февр. 2026 г., 12:35 UTC

Отчет

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

29 янв. 2026 г., 13:00 UTC

Обсуждения рынка

Отчет

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Сравнение c конкурентами

Изменение цены

Sanofi Прогноз

Целевая цена

By TipRanks

22.26% рост

Прогноз на 12 месяцев

Средняя 53 USD 22.26%

Максимум 57 USD

Минимум 50 USD

Основано на мнении 3 аналитиков Wall Street, спрогнозировавших целевые цены для Sanofi на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

3 ratings

Покупка

Удержание

Продажа

Основано на мнении 3 аналитиков, присваивавших рейтинги акциям Sanofi – Данные за последние 3 месяца.

Техническая оценка

By Trading Central

51.665 / 52.38Поддержка и Сопротивление

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.